173 related articles for article (PubMed ID: 29535424)
1. Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics.
Shen P; Jing Y; Zhang R; Cai MC; Ma P; Chen H; Zhuang G
Oncogene; 2018 May; 37(22):3039-3044. PubMed ID: 29535424
[TBL] [Abstract][Full Text] [Related]
2. Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder.
Liu F; Li Y; Ying D; Qiu S; He Y; Li M; Liu Y; Zhang Y; Zhu Q; Hu Y; Liu L; Li G; Pan W; Jin W; Mu J; Cao Y; Liu Y
Signal Transduct Target Ther; 2021 Feb; 6(1):55. PubMed ID: 33563892
[TBL] [Abstract][Full Text] [Related]
3. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
4. Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer.
Vandekerkhove G; Todenhöfer T; Annala M; Struss WJ; Wong A; Beja K; Ritch E; Brahmbhatt S; Volik SV; Hennenlotter J; Nykter M; Chi KN; North S; Stenzl A; Collins CC; Eigl BJ; Black PC; Wyatt AW
Clin Cancer Res; 2017 Nov; 23(21):6487-6497. PubMed ID: 28760909
[No Abstract] [Full Text] [Related]
5. Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma.
Ohmoto A; Sato Y; Asaka R; Fukuda N; Wang X; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Toshiyasu T; Mitani H; Takeuchi K; Mori S; Takahashi S
Mod Pathol; 2021 Nov; 34(11):1979-1989. PubMed ID: 34247193
[TBL] [Abstract][Full Text] [Related]
6. Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma.
Shamir ER; Devine WP; Pekmezci M; Umetsu SE; Krings G; Federman S; Cho SJ; Saunders TA; Jen KY; Bergsland E; Jones K; Kim GE; Kakar S; Chiu CY; Joseph NM
Mod Pathol; 2019 Feb; 32(2):290-305. PubMed ID: 30237525
[TBL] [Abstract][Full Text] [Related]
7. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
Moss TJ; Qi Y; Xi L; Peng B; Kim TB; Ezzedine NE; Mosqueda ME; Guo CC; Czerniak BA; Ittmann M; Wheeler DA; Lerner SP; Matin SF
Eur Urol; 2017 Oct; 72(4):641-649. PubMed ID: 28601352
[TBL] [Abstract][Full Text] [Related]
9. Biology and evolution of poorly differentiated neuroendocrine tumors.
Rickman DS; Beltran H; Demichelis F; Rubin MA
Nat Med; 2017 Jun; 23(6):1-10. PubMed ID: 28586335
[TBL] [Abstract][Full Text] [Related]
10. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.
Ross JS; Wang K; Gay LM; Al-Rohil RN; Nazeer T; Sheehan CE; Jennings TA; Otto GA; Donahue A; He J; Palmer G; Ali S; Nahas M; Young G; Labrecque E; Frampton G; Erlich R; Curran JA; Brennan K; Downing SR; Yelensky R; Lipson D; Hawryluk M; Miller VA; Stephens PJ
Clin Cancer Res; 2014 Jan; 20(1):68-75. PubMed ID: 24192927
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.
Hedegaard J; Lamy P; Nordentoft I; Algaba F; Høyer S; Ulhøi BP; Vang S; Reinert T; Hermann GG; Mogensen K; Thomsen MBH; Nielsen MM; Marquez M; Segersten U; Aine M; Höglund M; Birkenkamp-Demtröder K; Fristrup N; Borre M; Hartmann A; Stöhr R; Wach S; Keck B; Seitz AK; Nawroth R; Maurer T; Tulic C; Simic T; Junker K; Horstmann M; Harving N; Petersen AC; Calle ML; Steyerberg EW; Beukers W; van Kessel KEM; Jensen JB; Pedersen JS; Malmström PU; Malats N; Real FX; Zwarthoff EC; Ørntoft TF; Dyrskjøt L
Cancer Cell; 2016 Jul; 30(1):27-42. PubMed ID: 27321955
[TBL] [Abstract][Full Text] [Related]
12. Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile.
Hoffman-Censits J; Choi W; Pal S; Trabulsi E; Kelly WK; Hahn NM; McConkey D; Comperat E; Matoso A; Cussenot O; Cancel-Tassin G; Fong MHY; Ross J; Madison R; Ali S
Eur Urol Oncol; 2021 Apr; 4(2):297-300. PubMed ID: 32061548
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas.
Lee SM; Sung CO
Sci Rep; 2021 Mar; 11(1):6203. PubMed ID: 33737597
[TBL] [Abstract][Full Text] [Related]
14. Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations.
Simbolo M; Barbi S; Fassan M; Mafficini A; Ali G; Vicentini C; Sperandio N; Corbo V; Rusev B; Mastracci L; Grillo F; Pilotto S; Pelosi G; Pelliccioni S; Lawlor RT; Tortora G; Fontanini G; Volante M; Scarpa A; Bria E
J Thorac Oncol; 2019 Sep; 14(9):1651-1661. PubMed ID: 31085341
[TBL] [Abstract][Full Text] [Related]
15. Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin.
Scott SN; Ostrovnaya I; Lin CM; Bouvier N; Bochner BH; Iyer G; Solit D; Berger MF; Lin O
Cancer Cytopathol; 2017 Jun; 125(6):416-426. PubMed ID: 28339163
[TBL] [Abstract][Full Text] [Related]
16. A comparison of adult rhabdomyosarcoma and high-grade neuroendocrine carcinoma of the urinary bladder reveals novel PPP1R12A fusions in rhabdomyosarcoma.
Gupta S; Sosa CP; Kosari F; Folpe A; Bhinge KN; Yang L; Agahi A; Johnson SH; Frank I; Boorjian SA; Hansel DE; Al-Ahmadie HA; Reuter VE; Vasmatzis G; Jimenez RE; Herrera-Hernandez L; Cheville JC
Hum Pathol; 2019 Jun; 88():48-59. PubMed ID: 30946934
[TBL] [Abstract][Full Text] [Related]
17. Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis.
Chang MT; Penson A; Desai NB; Socci ND; Shen R; Seshan VE; Kundra R; Abeshouse A; Viale A; Cha EK; Hao X; Reuter VE; Rudin CM; Bochner BH; Rosenberg JE; Bajorin DF; Schultz N; Berger MF; Iyer G; Solit DB; Al-Ahmadie HA; Taylor BS
Clin Cancer Res; 2018 Apr; 24(8):1965-1973. PubMed ID: 29180607
[No Abstract] [Full Text] [Related]
18. Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer.
Shi MJ; Meng XY; Fontugne J; Chen CL; Radvanyi F; Bernard-Pierrot I
Genome Med; 2020 Sep; 12(1):85. PubMed ID: 32988402
[TBL] [Abstract][Full Text] [Related]
19. A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations.
Kobayashi H; Kosaka T; Nakamura K; Shojo K; Hongo H; Mikami S; Nishihara H; Oya M
BMC Med Genomics; 2021 Oct; 14(1):245. PubMed ID: 34627261
[TBL] [Abstract][Full Text] [Related]
20. The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary.
Wang B; Yao J; Ma R; Liu D; Lu Y; Shi G; An L; Xia A; Chen F; Pang S; Zhai X; Liu G; Chen S; Xu M; Song L; Xu H
Int J Cancer; 2021 Apr; 148(8):2036-2047. PubMed ID: 33403690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
